Biopharmaceutical company focused on the formulation and commercialization of innovative therapies using its proprietary hydrogel-based formulation technology.
Location: United States, Massachusetts, Bedford
Employees: 201-500
Total raised: $38M
Founded date: 2006
Investors 2
| Date | Name | Website |
| - | Ascension ... | ascensionv... |
| - | SV Health ... | svhealthin... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 29.01.2013 | Series D | $24M | - |
| 03.02.2011 | Series D | $14M | - |
Mentions in press and media 16
| Date | Title | Description |
| 03.09.2024 | Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer | Cambridge, UK, 3 September 2024 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces the appointment of Antony Mattessich as its Chief Executive Of... |
| 11.03.2024 | Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results | Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and PAXTRAVA™ in Glaucoma Expected in Q2 202... |
| 11.03.2024 | Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results | - |
| 05.03.2024 | Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024 | - |
| 23.07.2021 | OCULAR THERAPEUTIX : ANNOUNCES SECOND QUARTER 2021 PRELIMINARY NET PRODUCT REVENUE OF $11.7 MILLION | BEDFORD, Mass. - Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, reported preliminary net pro... |
| 22.07.2021 | Ocular Therapeutix : trade; Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million | Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported preliminary net product revenu... |
| 01.03.2021 | Ocular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease | BEDFORD, Mass.--(BUSINESS WIRE)--Mar 1, 2021-- Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the e... |
| 22.01.2015 | Ocular Therapeutix launches dry-eye trial | Ocular Therapeutix (NSDQ:OCUL) said it enrolled the 1st patient in a Phase II study of its bioresorbable eye plug in the treatment of inflammatory dry-eye disease. The punctum plug, which is inserted in the tear-duct region of the eye, uses... |
| 17.07.2014 | Ocular Therapeutix looks to raise $80M in IPO | Medtech Wall Street news for the week of July 14, 2014 | Ocular Therapeutix sets terms for IPO July 11, 2014 by Brad Perriello Ocular Therapeutix is looking to raise as much as $80 million in a forthcoming initial public offering, the company said today. Bedford, Mass.-based Ocular Therapeutix sa... |
| 10.06.2013 | Ocular Therapeutix Secures Additional financing in Series D Round | Ocular Therapeutix, a Bedford, MA-based developer of ophthalmic therapeutic products, secured additional financing in its Series D round. The amount of the transaction was not disclosed. Backers included Baxter Ventures, which acquired a mi... |
Show more